Biomerica (NASDAQ:BMRA) Posts Earnings Results, Beats Estimates By $0.76 EPS

Biomerica (NASDAQ:BMRA) announced its quarterly earnings results on Monday. The company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.76, Zacks reports. The business had revenue of $0.99 million during the quarter, compared to analysts’ expectations of $3.63 million. Biomerica had a negative return on equity of 83.73% and a negative net margin of 90.29%.

Biomerica Stock Down 2.3%

BMRA opened at $2.08 on Tuesday. The firm has a market cap of $6.28 million, a P/E ratio of -2.24 and a beta of 0.20. Biomerica has a 52 week low of $1.87 and a 52 week high of $4.88. The business’s fifty day simple moving average is $2.14 and its 200 day simple moving average is $2.44.

Institutional Trading of Biomerica

An institutional investor recently raised its position in Biomerica stock. DRW Securities LLC lifted its stake in shares of Biomerica, Inc. (NASDAQ:BMRA) by 62.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 16,925 shares of the company’s stock after acquiring an additional 6,533 shares during the period. DRW Securities LLC owned 0.56% of Biomerica worth $43,000 as of its most recent SEC filing. 22.28% of the stock is currently owned by institutional investors.

Biomerica Company Profile

Biomerica, Inc is a developer, manufacturer and marketer of in vitro diagnostic tests for clinical diagnostic, life science research and food safety applications. The company’s product portfolio includes enzyme-linked immunosorbent assays (ELISAs), lateral flow immunoassays, point-of-care devices and specialty reagents designed to aid in the detection and monitoring of gastrointestinal, metabolic and autoimmune conditions. Biomerica’s diagnostics are used by hospitals, clinical and reference laboratories, and research institutions seeking solutions for early disease detection and patient management.

Key offerings from Biomerica include serological tests for celiac disease and gluten intolerance, quantitative assays for colorectal cancer screening markers such as M2-PK, and a range of point-of-care kits for metabolic monitoring.